非典型溶血性尿毒症综合征肾移植后的预防性依库珠单抗治疗 - Suppr

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

作者信息

Zimmerhackl Lothar Bernd, Hofer Johannes, Cortina Gérard, Mark Walter, Würzner Reinhard, Jungraithmayr Therese C, Khursigara Gus, Kliche Kay O, Radauer Wolfgang

出版信息

N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060.

DOI:10.1056/NEJMc1001060

PMID:20445192

Abstract

摘要

相似文献

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.非典型溶血性尿毒症综合征肾移植后的预防性依库珠单抗治疗

N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.依库珠单抗治疗非典型溶血性尿毒综合征和其他补体介导的肾脏疾病。

Curr Opin Pediatr. 2013 Apr;25(2):225-31. doi: 10.1097/MOP.0b013e32835df4a3.

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.在第三次肾移植治疗伴 CFH 突变的非典型溶血尿毒症综合征后，使用依库珠单抗治疗并停止血浆置换以维持肾功能。

Am J Kidney Dis. 2010 Apr;55(4):708-11. doi: 10.1053/j.ajkd.2009.08.011. Epub 2009 Oct 25.

Eculizumab for atypical hemolytic-uremic syndrome.依库珠单抗用于非典型溶血性尿毒症综合征

N Engl J Med. 2009 Jan 29;360(5):542-4. doi: 10.1056/NEJMc0808527.

Actual and future strategies for transplantation in atypical HUS associated with mutations in factor H.与补体因子H突变相关的非典型溶血尿毒综合征的当前及未来移植策略

Pediatr Transplant. 2011 May;15(3):225-8. doi: 10.1111/j.1399-3046.2010.01345.x.

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.活体供肾移植治疗非典型溶血尿毒综合征：病例系列研究。

Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16.

Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.依库珠单抗治疗肾移植后复发非典型溶血尿毒综合征患者17个月的安全性和疗效：病例报告

Transplant Proc. 2010 Dec;42(10):4353-5. doi: 10.1016/j.transproceed.2010.09.125.

Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.1例伴有补体H因子突变的非典型溶血尿毒综合征（aHUS）患者停用依库珠单抗治疗后aHUS复发。

Ann Hematol. 2013 Jun;92(6):845-6. doi: 10.1007/s00277-012-1622-z. Epub 2012 Nov 15.

Liver transplantation for aHUS: still needed in the eculizumab era?依库珠单抗时代，非典型溶血性尿毒症综合征仍需肝移植吗？

Pediatr Nephrol. 2016 May;31(5):759-68. doi: 10.1007/s00467-015-3278-0. Epub 2015 Nov 24.

Eculizumab and renal transplantation in a patient with CAPS.依库珠单抗与1例伴有冷球蛋白血症性血管炎综合征患者的肾移植

N Engl J Med. 2010 May 6;362(18):1744-5. doi: 10.1056/NEJMc0910965.

引用本文的文献

First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient.肾移植患者中首例成功将复发型非典型溶血性尿毒症综合征长期依库珠单抗治疗转换为ravulizumab治疗的报告。

Transpl Int. 2022 Oct 3;35:10846. doi: 10.3389/ti.2022.10846. eCollection 2022.

Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome.瑞武利单抗用于遗传性非典型溶血性尿毒症综合征的活体供肾移植术前预防

Transplant Direct. 2022 Jan 26;8(2):e1289. doi: 10.1097/TXD.0000000000001289. eCollection 2022 Feb.

Pediatric Atypical Hemolytic Uremic Syndrome Advances.儿科非典型溶血尿毒综合征的研究进展。

Cells. 2021 Dec 18;10(12):3580. doi: 10.3390/cells10123580.

Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseases.肾移植后补体介导的肾脏疾病——当前原发性和复发性疾病的诊断和治疗选择

World J Transplant. 2018 Oct 22;8(6):203-219. doi: 10.5500/wjt.v8.i6.203.

Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease.肾移植后血栓性微血管病：当前对新发及复发性疾病的认识

World J Transplant. 2018 Sep 10;8(5):122-141. doi: 10.5500/wjt.v8.i5.122.

Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan.日本近畿地区携带C3 p.I1157T变异的非典型溶血尿毒综合征患者的临床表现

Clin Appl Thromb Hemost. 2018 Nov;24(8):1301-1307. doi: 10.1177/1076029618771750. Epub 2018 Apr 25.

Pharmacologic Complement Inhibition in Clinical Transplantation.临床移植中的药理学补体抑制

Curr Transplant Rep. 2017;4(2):91-100. doi: 10.1007/s40472-017-0148-7. Epub 2017 Apr 20.

Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.以依库珠单抗作为首选治疗肾移植后非典型溶血性尿毒症综合征的长期预后

PLoS One. 2017 Nov 14;12(11):e0188155. doi: 10.1371/journal.pone.0188155. eCollection 2017.

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.用于血栓性微血管病的补体C5抑制疗法：证据不断积累，但并非万灵药。

Clin Kidney J. 2017 Oct;10(5):600-624. doi: 10.1093/ckj/sfx081. Epub 2017 May 8.

Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies.依库珠单抗与重组人可溶性血栓调节蛋白联合治疗对一名因抗H因子自身抗体导致非典型溶血尿毒综合征的7岁女童的疗效。

CEN Case Rep. 2014 May;3(1):110-117. doi: 10.1007/s13730-013-0097-7. Epub 2013 Sep 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献